/
ADCT
$1.05-$0.18 (-14.63%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$156.4M
127M shares
52-week range
$0.78 – $4.98
6% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
Change$-25.06
ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
www.adctherapeutics.com- Employees
- 193
- IPO / List date
- May 15, 2020
- HQ
- EPALINGES, V8
Held by traders on TradeandTell
No one on the platform currently holds ADCT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 299,278 | $1.1M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2005-05-10 | 1-for-7reverse |
Recent trades on TradeandTell
No one on the platform has traded ADCT yet.
